最新の財務諸表(Form-10K)によると、Honeywell International Incの総資産は$74,115で、純利益は$5,139です。
THARの主要な財務比率は何ですか?
Honeywell International Incの流動比率は1.26、純利益率は13.72、1株当たり売上高は$58.24です。
Canton Strategic Holdings Incの収益はセグメントまたは地域別にどのように分けられていますか?
現在、Honeywell International Inc のデータは利用できません。
Canton Strategic Holdings Incは収益を上げていますか?
はい、最新の財務諸表によると、Honeywell International Incの純利益は$5,139です。
Canton Strategic Holdings Incに負債はありますか?
はい、Honeywell International Incの負債は58,675です。
Canton Strategic Holdings Incの発行済株式数は何株ですか?
Honeywell International Incの総発行済株式数は634.88株です。
主要データ
前終値
$4.48
始値
$4.48
当日レンジ
$4.36 - $4.8
52週レンジ
$0.952 - $9.08
取引高
622.7K
平均取引高
807.7K
配当利回り
--
1株当たり利益(TTM)
-3.68
時価総額
$187.3M
Tharimmune, Inc.とは何ですか?
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.